1Trepicchio WL, Bozza M, Pedneault G, et al. Recombinant human IL- 11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol, 1996, 157:3627 - 3634.
2Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol, 2000, 42:829 - 830.
3Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol, 2001, 144:587 -589.
4Ferenczi K, Burack L, Pope M, et al. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun,2000, 14:63 - 78.
5Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol, 2001, 137:893 -8
6Krueger JG, Walters lB, Miyazawa M, et al. Successful in vivo blockade of CD25 ( high-affinity interleukin .2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol, 2000, 43:448-458.
7Reich K, Garbe C, Blaschke V, et al. Response of psoriasis to interleukin - 10 is associated with suppression of cutaneous type l inflammation, downregulation of the epidermal interleukin - 8/CXCR2 pathway and normalization of keratinocyte maturation. J I
8Bagel J, Garland WT, Breneman D, et al. Administration of DAB3891L- 2 to patients with recalcitrant psoriasis: a double-blind,phase I1 muhicenter trial. J Am Acad Dermatol, 1998, 38:938 -944.
9Cather J, Menter A. Novel therapies for psoriasis. Am J Clin Dermatol, 2002, 3:159- 173.
10Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol, 2002, 46:1 - 23.
